Biomea Fusion reports BMF-219 preclinical data: HbA1c reduction of 3.5% vs. liraglutide's 1.7% in T2D rat model

Biomea Fusion, Inc.

BMF-219 lowered HbA1c by 3.5% vs. liraglutide 1.7% in ZDF rat model; effect maintained through 2-week drug washout.
BMF-219 restored HOMA-B index to normal range (>201) over 4 weeks, indicating improved beta-cell function.
BMF-219 treatment resulted in 13% body weight reduction over 4 weeks and lowered total cholesterol and triglycerides.
Company reaffirms IND submission for BMF-219 in type 2 diabetes in second half of 2022.
Data presented at EASD Annual Meeting on September 20, 2022 in Stockholm, Sweden.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.